A New Generation of Fully Human anti-CTLA-4 Heavy Chain Only Antibody

BCMA x CD3 Bispecific Antibody – A novel HBICE™-based Molecule with Efficient Tumor Killing and Minimal Cytokine Release

HBM1007 – A Highly Potent Anti-CD73 mAb Candidate For Mono And Combination IO Therapy

Novel Monoclonal Antibodies (mAbs) Targeting Human CCR8 Provide Potential Candidates for Next Generation Cancer Immunotherapy

HBM1022, a Novel Anti-CCR8 Antibody, Depletes Tumor-infiltrating Regulatory T cells via Enhanced ADCC Activity, Mediates Potent Anti-Tumor Activity

HCAb Based Bispecific Immune Cell Engager (HBICE) Platform Enables Fast And Convenient Generation of the Next Generation Bispecific Antibodies with High Potency, Promising Safety Profiles and Excellent Developability

Discovery of potent and functional human antibodies against a new B7-family member, B7H7, for cancer immunotherapy

Development of fully human T-cell engaging bispecific antibodies targeting B7H4

Preclinical evaluation of HBM7022, an HBICE™ 2+1 CLDN18.2 x CD3 bispecific antibody, for gastric cancer

Cell Engager Summit Exclusive Speaker Interview

Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein

A human monoclonal antibody blocking SARS-CoV-2 infection

Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies

SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model

Safety, tolerability, pharmacokinetics, and pharmacodynamics of HBM9161, a novel FcRn inhibitor, in a phase I study for healthy Chinese volunteers

Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study

TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China

An anti-CTLA-4 heavy chain-only antibody with enhanced T reg depletion shows excellent preclinical efficacy and safety profile

Innovative B7H4 x CD3 & B7H4 x 4-1BB Bispecificsfor Solid Tumor Therapies